AI Article Synopsis
- The study aimed to determine if colchicine can inhibit NLRP3 inflammasome activation in COVID-19 patients.
- Analysis included a controlled clinical trial where serum levels of inflammasome products were measured before and after colchicine treatment.
- Results showed colchicine decreased the need for oxygen supplementation and hospital stay, while reducing some inflammasome products, indicating its potential to combat inflammation in COVID-19.
Article Abstract
Objective: To evaluate whether colchicine treatment was associated with the inhibition of NLRP3 inflammasome activation in patients with COVID-19.
Methods: We present a post hoc analysis from a double-blinded placebo-controlled randomized clinical trial (RCT) on the effect of colchicine for the treatment of COVID-19. Serum levels of NOD-like receptor protein 3 (NLRP3) inflammasome products-active caspase-1 (Casp1p20), IL-1β, and IL-18-were assessed at enrollment and after 48-72 h of treatment in patients receiving standard-of-care (SOC) plus placebo vs. those receiving SOC plus colchicine. The colchicine regimen was 0.5 mg tid for 5 days, followed by 0.5 mg bid for another 5 days.
Results: Thirty-six patients received SOC plus colchicine, and thirty-six received SOC plus placebo. Colchicine reduced the need for supplemental oxygen and the length of hospitalization. On Days 2-3, colchicine lowered the serum levels of Casp1p20 and IL-18, but not IL-1β.
Conclusion: Treatment with colchicine inhibited the activation of the NLRP3 inflammasome, an event triggering the 'cytokine storm' in COVID-19.
Trial Registration Numbers: RBR-8jyhxh.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013297 | PMC |
| http://dx.doi.org/10.1007/s00011-023-01718-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Commentary: BAFF blockade attenuates DSS-induced chronic colitis inhibiting NLRP3 inflammasome and NF-кB activation.
Front Immunol
December 2024
School of Medicine, Shenzhen University, Shenzhen, China.
Exploring the efficacy of (R)-PFI-2 hydrochloride in mitigating noise-induced hearing loss by targeting NLRP3 inflammasome and NF-κB pathway to reduce inner ear inflammation.
J Otol
October 2024
Department of Otorhinolaryngology, the First Hospital of Jilin University, Changchun, 130021, Jilin, China.
Noise-induced hearing loss (NIHL) is primarily driven by inflammatory processes within the cochlea, where noise exposure triggers the activation of the NOD-like receptor protein 3 (NLRP3) inflammasome, leading to an inflammatory cascade. The interaction between increased NLRP3 expression and NF-κB activity can further amplify cochlear inflammation. Our findings reveal that (R)-PFI-2 hydrochloride, a selective inhibitor of the SETD7 enzyme, effectively inhibits the activation of the cochlear NF-κB pathway, suppresses the release of pro-inflammatory factors, and prevents inflammasome assembly.
View Article and Find Full Text PDFHydrogen decreases susceptibility to AngII-induced atrial fibrillation and atrial fibrosis via the NOX4/ROS/NLRP3 and TGF-β1/Smad2/3 signaling pathways.
PLoS One
January 2025
Department of Cardiology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Atrial fibrillation (AF) represents the commonly occurring cardiac arrhythmia and the main factor leading to stroke and heart failure. Hydrogen (H2) is a gaseous signaling molecule that has the effects of anti-inflammation and antioxidation. Our study provides evidence that hydrogen decreases susceptibility to AngII-mediated AF together with atrial fibrosis.
View Article and Find Full Text PDFThe effect of NLRP3 inflammasome on cardiovascular prognosis in patients with acute coronary syndrome.
Sci Rep
January 2025
Department of Cardiology, Liaocheng People's Hospital Affiliated to Shandong First Medical University, Liaocheng, 252000, China.
The NOD‑like receptor protein domain associated protein 3 (NLRP3) inflammasome is critical in inflammatory responses and may be a valuable prognostic biomarker in acute coronary syndrome (ACS). We aimed to investigate the association between NLRP3 inflammasome levels and short-term outcomes in patients with ACS. We enrolled 295 patients with ACS who were monitored for 6 months for major adverse cardiovascular events (MACEs).
View Article and Find Full Text PDFApelin-13 Ameliorates Sepsis-induced Brain Injury by Activating Phosphatase and Tensin Homolog-induced Putative Kinase 1/Parkin-mediated Mitophagy and Modulating Nucleotide-binding Oligomerization Domain-like Receptor Pyrin Domain-Containing 3-driven Pyroptosis in Rats.
J Physiol Investig
January 2025
Department of Emergency, Shijiazhuang Traditional Chinese Medicine Hospital, Shijiazhuang, China.
Sepsis is a life-threatening condition that often results in severe brain injury, primarily due to excessive inflammation and mitochondrial dysfunction. This study aims to investigate the neuroprotective effects of Apelin-13, a bioactive peptide, in a rat model of sepsis-induced brain injury (SBI). Specifically, we examined the role of Apelin-13 in regulating mitophagy through the phosphatase and tensin homolog-induced putative kinase 1 (PINK1)/Parkin pathway and its impact on nucleotide-binding oligomerization domain-like receptor pyrin domain-containing 3 (NLRP3) inflammasome-mediated pyroptosis and oxidative stress.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!